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Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation
tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present
guidelines recommend continuous drug dosing for maintaining remission. There is no available data concerning
the optimal duration of dasatinib therapy. We report the case of an imatinib intolerant patient who succeeded a
complete molecular remission with dasatinib. Dasatinib was stopped bacause of intolerance, but complete
molecular remission was sustained for one year and minor molecular remission for 27 months after discontinuation
of dasatinib.
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Tyrosine kinase inhibitors specific for BCR-ABL, were a
major breakthrough in CML therapy. Second generation
tyrosine kinase inhibitors (dasatinib, nilotinib) are indi-
cated for imatinib resistant and intolerant patients.
Present guidelines recommend continuous drug dosing
for maintaining remission. There is no available data
concerning the optimal duration of dasatinib therapy.
We report the case of an imatinib intolerant patient who
succeeded a complete molecular remission with dasati-
nib. Dasatinib was stopped bacause of intolerance, but
complete molecular remission was sustained for one
year and minor molecular remission for 27 months after
discontinuation of dasatinib.
The introduction of tyrosine kinase inhibitors spe-
cific for BCR-ABL, were a major breakthrough in
CML therapy [1]. Approximately 30% of patients re-
ceiving imatinib as first-line therapy will discontinue
treatment by 5 years because of imatinib resistance or
drug toxicity [2].
Second generation TKIs (dasatinib, nilotinib) are indi-
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reproduction in any medium, provided the orto imatinib [3,4]. However, after stopping TKI adminis-
tration, relapse comes about inevitable, so the present
guidelines recommend continuous drug dosing [5].
While there is an ongoing prospective study with imati-
nib (Stop Imatinib study) [6], no available data arising
from controlled studies exists with dasatinib concerning
the optimal duration of therapy. Consequently, discon-
tinuation of dasatinib is not recommended outside of
clinical trials but remains an active area of research [7].
Our patient, a 84 year old lady with a chronic phase
CML was intolerant to imatinib. She was given dasatinib
as second line treatment. Though a reduced dose of
50 mg daily was applied, a complete molecular remission
developed within two months. After four months she
suspended taking the drug because of intolerance
(pleural effusion, congestive heart failure, Adams-Stokes
syndrome had been developed), but complete molecular
remission was lasting till one year after stopping dasati-
nib. The patient did not receive any kind of anti-CML
therapy during this year. After one year without any
TKI, the expression level of BCR/ABL major fusion gene
has increased gradually, but even now, 27 months after
stopping dasatinib treatment, the patient is still in minor
molecular remission (Figure 1).
Because of her several kind of comorbidities, her good
quality of life, the actual hematological remission andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Expression level of BCR-ABL major fusion gene at various time during therapy measured by real-time quantitative PCR using
ABL gene amplification as a control.
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peutical strategy is only watch and wait.
This is the first report about maintaining complete
molecular remission after one year of suspending dasati-
nib treatment.
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